about
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerCapecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancerSt. Gallen/Vienna 2015: A Brief Summary of the Consensus DiscussionAfatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.HER2 Dimerization Inhibitor Pertuzumab - Mode of Action and Clinical Data in Breast CancerHuman kallikrein 11: an indicator of favorable prognosis in ovarian cancer patientsLobular breast cancer: Clinical, molecular and morphological characteristics.Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study.ABC3 Consensus: Assessment by a German Group of ExpertsBreast Cancer Is Our Global Responsibility.14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German Perspective.ABC2 Consensus Conference on Advanced Breast Cancer: Brief Summary of the Consensus Panel on Saturday November 9, 2013AGO Recommendations for Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 201313th st. Gallen international breast cancer conference 2013: primary therapy of early breast cancer evidence, controversies, consensus - opinion of a german team of experts (zurich 2013).AGO Recommendations for Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2013.German adjuvant intergroup node-positive study: a phase III trial to compare oral ibandronate versus observation in patients with high-risk early breast cancer.AGO Recommendations for Diagnosis and Treatment of Patients with Early and Metastatic Breast Cancer: Update 2012.AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.Update 2010 of the German AGO Recommendations for the Diagnosis and Treatment of Early and Metastatic Breast Cancer - Chapter B: Prevention, Early Detection, Lifestyle, Premalignant Lesions, DCIS, Recurrent and Metastatic Breast Cancer.Patient's Anastrozole Compliance to Therapy (PACT) Program: Baseline Data and Patient Characteristics from a Population-Based, Randomized Study Evaluating Compliance to Aromatase Inhibitor Therapy in Postmenopausal Women with Hormone-Sensitive EarlyAdjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.From genomic data analysis to drug development: a new generation of trials using molecular marker assessment in breast cance.West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and TFirst-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HIntense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patientsPhase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.Fluorescence Analysis of Vitamin D Receptor Status of Circulating Tumor Cells (CTCS) in Breast Cancer: From Cell Models to Metastatic PatientsPhase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast CancerAssessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects
P50
Q24626194-676A2F08-27C3-4E62-A774-7A1188AB3F96Q24633167-0334B946-67EF-4764-AA2B-C3E63882BE3DQ26801473-6FB3D57D-67E1-41C6-9E4F-F9390A836CCCQ27853332-0548460D-27D9-4634-AD00-6E0151146CF2Q28237833-A2C7DE3C-059D-4510-ACEA-1D578D5607F9Q28278815-F2A78B4C-AA66-47CB-89FA-FA9F10DB5AAEQ30250071-6910321A-0CAD-4AD0-800B-A6F01B270036Q30313653-EB2040F7-6FAE-4CDB-90A1-9C028672E0BAQ30315301-5FF4F8D0-DBC2-4155-A7FD-96424C4C1AC3Q30315429-E7E1D8FB-DA10-4A8F-A067-1DB042F78D28Q30315970-F5547EF8-7FC0-4254-9683-F18C50BB485CQ30317450-0F9A6831-BC15-4CF2-9D87-41998C35D56BQ30317519-C12081DB-3CD3-410A-BF66-23594E9C0401Q30317569-3082DAA7-C2AF-4462-AE4C-54DDBF319788Q30317570-852E7E85-E3C2-45A6-9DFA-D37CB6D73474Q30317579-B4ADF71F-168C-4B7D-9799-27CDAC3F59A7Q30317734-26BF1AFE-2168-40A9-9E80-6F668885BDC9Q30317757-7D81EFB9-D734-4102-8B4B-84AF11CF93AFQ30318240-189D016B-DD90-4E2D-AB69-1EA380661539Q30318419-0AD5F3BF-2875-4568-A917-FE3E1E9CCD63Q30318823-562DA949-5405-4049-BB13-89C0A3386A52Q30732631-7F02ECAE-1A94-4882-8B8E-895E9C132DFDQ30758991-19029919-FE5E-43FF-AFB6-B5CDFD1791C2Q30923203-C4F364F8-F8B9-44D4-8743-21F61D8881C0Q31050268-4C828EE3-D6F9-473F-8873-8D5B22C8A407Q33384086-9FFC2696-ACEE-4712-B8BC-DDAF08FF6B15Q33394340-71292ADE-C439-4E38-AC01-14DFDD42F13AQ33414622-0FB299C4-B14B-4410-90C1-34ED6ED5876AQ33416422-97661C8B-0B8B-4C4B-ABA8-B8D9928E7104Q33423263-00EB8DBE-AE48-4383-8EF3-7D2B9199D28AQ33443385-7DE96336-CC51-4FDB-A443-E0D429AA8B30Q33533553-910B5D66-E7A6-47B3-AAC1-D9C7102EF243Q33574416-E3FFE67D-6904-4590-8728-B57AFF21EE85Q33591741-2D4FE8DF-82D0-449D-BB00-2B566D5669D6Q33794403-F297D176-2E43-4BB3-9203-6BB11EB5A818Q33839150-C0E148A6-D044-4174-8AE4-813BEBFF7C88Q34022546-34CE0C51-3D3B-4DD2-A5C7-0E487E366F50Q34042709-C79A9D96-2D17-41CC-ADF5-ED320541AFE3Q34095748-921703B6-CA99-4D36-84EC-7153850CF93CQ34095769-B48C7781-60FB-4C85-A263-2F7269ABC32B
P50
description
onderzoeker
@nl
name
Nadia Harbeck
@ast
Nadia Harbeck
@en
Nadia Harbeck
@es
Nadia Harbeck
@sl
type
label
Nadia Harbeck
@ast
Nadia Harbeck
@en
Nadia Harbeck
@es
Nadia Harbeck
@sl
prefLabel
Nadia Harbeck
@ast
Nadia Harbeck
@en
Nadia Harbeck
@es
Nadia Harbeck
@sl